AMAG Pharma Appoints Pharmacovigilance VP

Judith Johnson, M.D., has rejoined AMAG Pharmaceuticals as vice president of pharmacovigilance and pharmacoepidemiology, responsible for all pharmacovigilance functions, including product safety surveillance, aggregate safety reporting, pharmacoepidemiology and risk management. She will also oversee the company’s compliance with FDA and regulatory requirements for Feraheme (ferumoxytol) Injection and MuGard Mucoadhesive Oral Wound Rinse.
 
For the past ten years, Dr. Johnson has held leadership roles in pharmacovigilance and drug safety at companies including EMD Serono, Inc., AMAG, Genzyme and Parexel.  
 
“Judy brings with her a wealth of experience and ability in the areas of drug safety and risk management, which will be critical for the future success of AMAG as we work to build a diversified, multi-product pharmaceutical company,” said Steven Caffe, M.D., senior vice president, chief development and regulatory officer at AMAG